EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Overcoming Resistance to Immune Checkpoint Blockade in Liver Cancer with Combination Therapy: Stronger Together?

Wiebke Werner, Maria Kuzminskaya, Isabella Lurje, Frank Tacke, Linda Hammerich

Seminars in Liver Disease · 01.05.2024 · 44 (02) · 159-179

DOI: 10.1055/a-2334-8311 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Seminars in Liver Disease, erschienen am 01.05.2024. Verfasst von Wiebke Werner und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatology and Gastroenterology, Charité Universitaetsmedizin Berlin, Berlin, Germany. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Liver Neoplasms, Carcinoma, Hepatocellular, Tumor Microenvironment. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 293 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Else Kröner-Fresenius-Stiftung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Primary liver cancer, represented mainly by hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (CCA), is one of the most common and deadliest tumors worldwide. While surgical resection or liver transplantation are the best option in early disease stages, these tumors often present in advanced stages and systemic treatment is required to improve survival time. The emergence of immune checkpoint inhibitor (ICI) therapy has had a positive impact especially on the treatment of advanced cancers, thereby establishing immunotherapy as part of first-line treatment in HCC and CCA. Nevertheless, low response rates reflect on the usually cold or immunosuppressed tumor microenvironment of primary liver cancer. In this review, we aim to summarize mechanisms of resistance leading to tumor immune escape with a special focus on the composition of tumor microenvironment in both HCC and CCA, also reflecting on recent important developments in ICI combination therapy. Furthermore, we discuss how combination of ICIs with established primary liver cancer treatments (e.g. multikinase inhibitors and chemotherapy) as well as more complex combinations with state-of-the-art therapeutic concepts may reshape the tumor microenvironment, leading to higher response rates and long-lasting antitumor immunity for primary liver cancer patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsLiver NeoplasmsCarcinoma, HepatocellularTumor MicroenvironmentDrug Resistance, NeoplasmCholangiocarcinomaAntineoplastic Combined Chemotherapy ProtocolsHumansBile Duct NeoplasmsTumor EscapeImmunotherapyAnimals

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Hepatology and Gastroenterology, Charité Universitaetsmedizin Berlin, Berlin, Germany.

Förderung

  • Deutsche Forschungsgemeinschaft
  • Else Kröner-Fresenius-Stiftung

Zitieren

APA

Werner, W., Kuzminskaya, M., Lurje, I., Tacke, F., & Hammerich, L. (2024). Overcoming Resistance to Immune Checkpoint Blockade in Liver Cancer with Combination Therapy: Stronger Together?. Seminars in Liver Disease, 44(02), 159-179. https://doi.org/10.1055/a-2334-8311

Vancouver

Werner W, Kuzminskaya M, Lurje I, Tacke F, Hammerich L. Overcoming Resistance to Immune Checkpoint Blockade in Liver Cancer with Combination Therapy: Stronger Together?. Seminars in Liver Disease. 2024;44(02):159-179. doi:10.1055/a-2334-8311

BibTeX
@article{Werner2024,
  author = {Werner, Wiebke and Kuzminskaya, Maria and Lurje, Isabella and Tacke, Frank and Hammerich, Linda},
  title = {Overcoming Resistance to Immune Checkpoint Blockade in Liver Cancer with Combination Therapy: Stronger Together?},
  journal = {Seminars in Liver Disease},
  year = {2024},
  volume = {44},
  number = {02},
  pages = {159--179},
  doi = {10.1055/a-2334-8311}
}
Kostenlos starten →